A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial
Tine Ottenbourgs, Toon van Gorp, Frédéric Kridelka, Thaïs Baert, Hannelore Denys, Frédéric Selle, Inge Baas, Anne-Sophie Van Rompuy, Diether Lambrechts, Els Van Nieuwenhuysen
International Journal of Gynecologic Cancer Mar 2024, ijgc-2023-005189; DOI: 10.1136/ijgc-2023-005189